Promise of adeno-associated virus as a gene therapy vector for cardiovascular diseases.

about

Cardiac optogenetics: the next frontier.

P2860

Q47743636-EEEF14EB-90C9-443B-9708-8DAB8003863F

P2860

Promise of adeno-associated virus as a gene therapy vector for cardiovascular diseases.

Item

http://www.wikidata.org/entity/Q39356341

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Promise of adeno-associated virus as a gene therapy vector for cardiovascular diseases.

@en

Promise of adeno-associated virus as a gene therapy vector for cardiovascular diseases.

@nl

type

Item

label

Promise of adeno-associated virus as a gene therapy vector for cardiovascular diseases.

@en

Promise of adeno-associated virus as a gene therapy vector for cardiovascular diseases.

@nl

prefLabel

Promise of adeno-associated virus as a gene therapy vector for cardiovascular diseases.

@en

Promise of adeno-associated virus as a gene therapy vector for cardiovascular diseases.

@nl

P1476

Promise of adeno-associated virus as a gene therapy vector for cardiovascular diseases.

@en

P2093

Abesh Bera

http://www.w3.org/2001/XMLSchema#string

P2860

Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a.

The Global Burden of Ischemic Heart Disease in 1990 and 2010: The Global Burden of Disease 2010 Study

Targeted beta-adrenergic receptor kinase (betaARK1) inhibition by gene transfer in failing human hearts

Modulation of cardiac contractility by the phospholamban/SERCA2a regulatome

Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy

Cell-type-specific characteristics modulate the transduction efficiency of adeno-associated virus type 2 and restrain infection of endothelial cells.

Adeno-associated virus serotype 2 induces cell-mediated immune responses directed against multiple epitopes of the capsid protein VP1

Myocardial adeno-associated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure

Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy

Enhanced beta2-adrenergic receptor (beta2AR) signaling by adeno-associated viral (AAV)-mediated gene transfer

P2888

s10741-017-9622-7

P304

795-823

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10741-017-9622-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Dwaipayan Sen

P577

2017-06-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28589503

http://www.w3.org/2001/XMLSchema#string

P921

gene therapy

vector-borne disease

cardiovascular disease

Promise of adeno-associated virus as a gene therapy vector for cardiovascular diseases.

about

P2860

P2860

Promise of adeno-associated virus as a gene therapy vector for cardiovascular diseases.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921